AbbVie Facing Class Action Following Stock Price Drops Linked to Xeljanz, Rinvoq Safety Concerns
April 7, 2022 AbbVie faces a class action that alleges the pharma co. misled investors by “condition[ing]” them to believe Rinvoq was far safer than Xeljanz.